Analytical Data
-
Gene name
MYEOV2
- Application
-
Alternative Names
COPS9; MYEOV2; COP9 signalosome complex subunit 9; CSN acidic protein; CSNAP; Myeloma-overexpressed gene 2 protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8WXC6
-
Expression Region
1-57 aa
-
AA Sequence
MKPAVDEMFP EGAGPYVDLD EAGGSTGLLM DLAANEKAVH ADFFNDFEDL FDDDDIQ
-
Molecular Weight
6.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYEOV2 (Myeloma Overexpressed 2) is a protein that has garnered attention in biomedical research due to its potential role in tumorigenesis and its involvement in various cancers, particularly multiple myeloma. Its overexpression has been linked to disease progression and poor prognosis, making it a significant target for therapeutic intervention and biomarker studies. Researchers have been investigating the functional mechanisms of MYEOV2, focusing on its interactions at the molecular level and how these contribute to cellular processes like proliferation, apoptosis, and immune evasion. The production of recombinant MYEOV2 protein is crucial for these studies, as it allows for detailed analysis of its biochemical properties, structural characteristics, and potential interactions with other molecules. By exploring the biochemical pathways influenced by MYEOV2 and its contribution to tumor pathology, researchers aim to uncover new therapeutic strategies that could harness this protein’s functions. Additionally, understanding MYEOV2's role could lead to the development of diagnostics that leverage its expression profiles, paving the way for personalized medicine approaches in cancer treatment. Overall, the research into MYEOV2 recombinant protein is pivotal for advancing our understanding of cancer biology and improving therapeutic outcomes for patients suffering from malignancies associated with this protein.
